Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The . gov means it’s official. Federal government websites often end in VSports app下载. gov or . mil. Before sharing sensitive information, make sure you’re on a federal government site. .

Https

The site is secure. The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely. V体育官网.

. 2014 Jul;2(4):509-517.
doi: 10.3892/mco.2014.293. Epub 2014 May 15.

Prognostic significance of the co-overexpression of fibroblast growth factor receptors 1, 2 and 4 in gastric cancer

Hideaki Murase  1 , Mikito Inokuchi  1 , Yoko Takagi  2 , Keiji Kato  1 , Kazuyuki Kojima  3 , Kenichi Sugihara  1
Affiliations

VSports - Prognostic significance of the co-overexpression of fibroblast growth factor receptors 1, 2 and 4 in gastric cancer

Hideaki Murase (VSports最新版本) et al. Mol Clin Oncol. 2014 Jul.

Abstract

The overexpression of fibroblast growth factor receptor (FGFR) 2 is an established prognostic factor and treatment target in gastric cancer. However, the roles of other FGFRs have not been fully elucidated. In this study, we investigated the correlations of the expression of FGFR1-4 with clinicopathological characteristics and outcomes in gastric cancer. Tumor samples were obtained from 222 patients with gastric adenocarcinoma who underwent gastrectomy between 2003 and 2007. The expression of each FGFR was measured in the tumors by immunohistochemical analysis. The overexpression of FGFR1, FGFR2 or FGFR4 was found to be significantly associated with tumor progression, including depth of invasion, lymph node metastasis, pathological stage and distant metastasis or recurrent disease. Patients exhibiting overexpression of FGFR1, FGFR2 or FGFR4 had a significantly poorer disease-specific survival (DSS; P<0. 001, P=0. 008 and P<0. 001, respectively). Moreover, the co-overexpression of all three FGFRs was significantly associated with a poorer DSS compared to the expression of none or only one of the FGFRs (P<0. 001 and P=0. 001, respectively) and it was found to be an independent prognostic factor (HR=1. 71, 95% CI: 1. 02-2. 85, P=0. 041). In conclusion, high expression of FGFR1, FGFR2 or FGFR4 was associated with tumor progression and poor survival in patients with gastric cancer VSports手机版. Similar to FGFR2, FGFR1 and FGFR4 may be considered as prognostic factors and treatment targets in gastric cancer. .

Keywords: fibroblast growth factor receptor; gastric cancer; immunohistochemical analysis V体育安卓版. .

PubMed Disclaimer

Figures

Figure 1
Figure 1
Immunostaining for fibroblast growth factor receptor (FGFR)1, FGFR2, FGFR3 and FGFR4. Representative primary gastric carcinomas exhibiting positive immunostaining for (A) FGFR1, (B) FGFR2, (C) FGFR3 and (D) FGFR4. Representative primary gastric carcinomas exhibiting immunostaining for FGFR1 with intensity scores of (E) 1 and (F) 3; immunostaining for FGFR2 with intensity scores of (G) 1 and (H) 3; immunostaining for FGFR3 with intensity scores of (I) 1 and (J) 2; and immunostaining for FGFR4 with intensity scores of (K) 1 and (L) 3. Representative metastatic lymph nodes exhibiting immunostaining for (M) FGFR1, (N) FGFR2 and (O) FGFR4. Magnification, ×400.
Figure 2
Figure 2
Survival of all patients. Kaplan-Meier curves for the disease-specific survival of patients with expression of (A) fibroblast growth factor receptor (FGFR)1, (B) FGFR2, (C) FGFR3 and (D) FGFR4 in the study group as a whole.
Figure 3
Figure 3
Survival of patients with co-overexpression of fibroblast growth factor receptor (FGFR)1, FGFR2 and FGFR4. Kaplan-Meier curves for the disease-specific survival of patients with co-overexpression of FGFR1, FGFR2 and FGFR4. a, none highly expressed; b, one highly expressed; c, two highly expressed; d, all highly expressed.
See this image and copyright information in PMC

References

    1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61:69–90. - "V体育安卓版" PubMed
    1. Brenner H, Rothenbacher D, Arndt V. Epidemiology of stomach cancer. Methods Mol Biol. 2009;472:467–477. - PubMed (V体育平台登录)
    1. Hartgrink HH, Jansen EP, van Grieken NC, van de Velde CJ. Gastric cancer. Lancet. 2009;374:477–490. - PMC - PubMed
    1. Cunningham D, Starling N, Rao S, et al. Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med. 2008;358:36–46. - PubMed
    1. Bang YJ, Van Cutsem E, Feyereislova A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 2010;376:687–697. - PubMed (VSports app下载)

LinkOut - more resources